Berenberg lowered the firm’s price target on Novo Nordisk (NVO) to DKK 400 from DKK 425 and keeps a Buy rating on the shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- Novo Nordisk (NVO) Gets New Chair — Can It Catch Up with Rival Eli Lilly in Obesity Market?
- Novo Nordisk Announces New Board Leadership Following Extraordinary Meeting
- Scholar Rock sees third-party facility ready for reinspection by end of year
- Novo Nordisk Announces Board Candidate Withdrawal Ahead of Meeting
- Investors Flee Mangoceuticals Stock (MGRX) after Eli Lilly and Novo Nordisk Deny Partnership